Regulus Therapeutics Inc.
RGLS
Rang in Aktien
#17340
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aktienkurs
$8.16
Zuletzt synchronisiert: 2025-06-26
Marktkapitalisierung
$234.57M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-56.96%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)
Kategorie
Healthcare
P/B-Verhältnis für Regulus Therapeutics Inc. (RGLS)
P/B-Verhältnis zum October 2026 TTM: 47.29
Laut den neuesten Finanzberichten und dem Aktienkurs von Regulus Therapeutics Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 47.29. Am Ende des Jahres 2022 lag das P/B-Verhältnis bei 2.90.
P/B-Verlauf für Regulus Therapeutics Inc. von 2002 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 47.29 | 88.70% |
| 2023 | 25.06 | 763.59% |
| 2022 | 2.90 | -35.79% |
| 2021 | 4.52 | -8.11% |
| 2020 | 4.92 | -51.71% |
| 2019 | 10.19 | 79.87% |
| 2018 | 5.66 | -19.96% |
| 2017 | 7.08 | 11.24% |
| 2016 | 6.36 | -8.92% |
| 2015 | 6.98 | 11.58% |
| 2014 | 6.26 | 17.25% |
| 2013 | 5.34 | -42.86% |
| 2012 | 9.34 | -75.23% |
| 2011 | 37.72 | -1.55% |
| 2010 | 38.31 | 0.97% |
| 2009 | 37.94 | -8.24% |
| 2008 | 41.34 | -2.27% |
| 2007 | 42.30 | -30.66% |
| 2006 | 61.01 | -34.31% |
| 2005 | 92.88 | -23.51% |
| 2004 | 121.42 | -15.67% |
| 2003 | 143.98 | -35.74% |
| 2002 | 224.08 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | -86.78% |
US
|
|
| 13.2547 | -71.97% |
US
|
|
| 4.208 | -91.10% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -86.93% |
NL
|
